SPTX
Seaport Therapeutics, Inc.
Seaport Therapeutics, Inc. (SPTX) has 10 SEC Form 4 filings (15 transaction rows) in the rolling window, disclosed by 2 distinct insiders. Most recent filing: Jun 24, 2026.
Insiders have net bought $20.0M over the trailing 6 months. The largest single insider purchase in this window was $19.8M by 10% Owner ARCH Venture Partners XII, LLC on May 4, 2026.
- Industry:Biotechnology
- CEO:Daphne Zohar
- Employees:58
- HQ:Boston, MA, US
- IPO:2026-05-01
Insider Buying
$20.0M
reported purchases (SEC code P)
Insider Selling
$0
reported sales (SEC code S)
Unique Insiders
2
in the rolling window
Market Cap
$1.3B
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
HOMBACH ROBERT J.First filing | Director | Purchase | 13,000 | $236K | Jun 24 | SEC ↗ |
ARCH Venture Partners XII, LLCFirst filing | 10% Owner | Purchase | 1,100,000 | $19.8M | May 4 | SEC ↗ |
Related companies
Seaport Therapeutics, Inc. is in the Healthcare sector.